{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:54:01Z","timestamp":1794650041017,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000},"content-version":"vor","delay-in-days":115,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. Emerging data suggest that these rare tumors exhibit immunogenicity, potentially benefiting from intensified immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SPENCER trial (NCT04187404) evaluates EO2401, an off-the-shelf in vivo peptide immunotherapy containing three synthetic HLA-A*02 restricted-peptides called OncoMimic and derived from human gut commensals that exhibit molecular mimicry to tumor-associated antigens (BIRC5, FOXM1, IL13RA2) combined with nivolumab in patients with locally advanced or metastatic adrenocortical carcinoma (ACC) or malignant pheochromocytoma\/ paraganglioma (PPGL). We performed T cell receptor (TCR) repertoire sequencing to profile the TCR architecture in ACC and characterize vaccination imprints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Here we show that ACC patients are characterized by a restricted peripheral T cell richness. EO2401 does not expand highly shared TCR clones across patients but diversifies pre-existing T cell clusters. These clusters are not converging on known neoantigen-specific TCRs but exhibit generation probabilities characteristic of public clones some of which being shared across patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that EO2401-based peptide immunotherapy combined with checkpoint inhibition can broaden and activate public, pre-existing T cell clusters, potentially enhancing tumor-specific immune responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-026-01755-8","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:45:32Z","timestamp":1783356332000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9789-5776","authenticated-orcid":false,"given":"Christoph","family":"Schulthei\u00df","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Besemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Willscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Paschold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tifanny","family":"Mersceman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Talpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Serger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Zippelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-5883","authenticated-orcid":false,"given":"Catharina Willemien","family":"Menke-van der Houven van Oordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4854-6075","authenticated-orcid":false,"given":"Dan","family":"Granberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Gedske Daugaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4728-0014","authenticated-orcid":false,"given":"Alexandra","family":"Triebig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Gauduchon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Eve","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Magalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Ch\u00eane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mascha","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","volume":"13","author":"M Fassnacht","year":"2025","unstructured":"Fassnacht, M., Puglisi, S., Kimpel, O. & Terzolo, M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diab. Endocrinol. 13, 438\u2013452 (2025).","journal-title":"Lancet Diab. Endocrinol."},{"key":"1755_CR2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht, M. et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1\u2013G46 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"1755_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1433582","volume":"15","author":"TJ Saavedra","year":"2024","unstructured":"Saavedra, T. J. et al. Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment. Front. Endocrinol. 15, 1433582 (2024).","journal-title":"Front. Endocrinol."},{"key":"1755_CR4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41574-019-0221-7","volume":"15","author":"J Crona","year":"2019","unstructured":"Crona, J. & Beuschlein, F. Adrenocortical carcinoma - towards genomics guided clinical care. Nat. Rev. Endocrinol. 15, 548\u2013560 (2019).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1755_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.mce.2011.12.008","volume":"351","author":"T Else","year":"2012","unstructured":"Else, T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol. Cell Endocrinol. 351, 66\u201370 (2012).","journal-title":"Mol. Cell Endocrinol."},{"key":"1755_CR6","volume":"37","author":"R Libe","year":"2023","unstructured":"Libe, R. & Huillard, O. Adrenocortical carcinoma: diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat. Res. Commun. 37, 100759 (2023).","journal-title":"Cancer Treat. Res. Commun."},{"key":"1755_CR7","doi-asserted-by":"publisher","first-page":"R27","DOI":"10.1530\/EJE-22-0260","volume":"187","author":"M Terzolo","year":"2022","unstructured":"Terzolo, M. & Fassnacht, M. Endocrine tumours: our experience with the management of patients with non-metastatic adrenocortical carcinoma. Eur. J. Endocrinol. 187, R27\u2013R40 (2022).","journal-title":"Eur. J. Endocrinol."},{"key":"1755_CR8","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","volume":"107","author":"M Daher","year":"2022","unstructured":"Daher, M. et al. Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral-center experience. J. Clin. Endocrinol. Metab. 107, 1239\u20131246 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1755_CR9","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","volume":"359","author":"U Sahin","year":"2018","unstructured":"Sahin, U. & Tureci, O. Personalized vaccines for cancer immunotherapy. Science 359, 1355\u20131360 (2018).","journal-title":"Science"},{"key":"1755_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","volume":"24","author":"PD Katsikis","year":"2024","unstructured":"Katsikis, P. D., Ishii, K. J. & Schliehe, C. Challenges in developing personalized neoantigen cancer vaccines. Nat. Rev. Immunol. 24, 213\u2013227 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"1755_CR11","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"1755_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1755_CR13","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","volume":"23","author":"CL Lorentzen","year":"2022","unstructured":"Lorentzen, C. L., Haanen, J. B., Met, O. & Svane, I. M. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 23, e450\u2013e458 (2022).","journal-title":"Lancet Oncol."},{"key":"1755_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng, M. et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol. Cancer 18, 128 (2019).","journal-title":"Mol. Cancer"},{"key":"1755_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03512-6","volume":"20","author":"C Ragone","year":"2022","unstructured":"Ragone, C. et al. Molecular mimicry between tumor associated antigens and microbiota-derived epitopes. J. Transl. Med. 20, 316 (2022).","journal-title":"J. Transl. Med."},{"key":"1755_CR16","doi-asserted-by":"publisher","unstructured":"Talpin, A., et al. Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer. J. Immunother Cancer 13. https:\/\/doi.org\/10.1136\/jitc-2024-010192 (2025).","DOI":"10.1136\/jitc-2024-010192"},{"key":"1755_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01776-0","volume":"22","author":"M Tagliamonte","year":"2023","unstructured":"Tagliamonte, M. et al. Molecular mimicry and cancer vaccine development. Mol. Cancer 22, 75 (2023).","journal-title":"Mol. Cancer"},{"key":"1755_CR18","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41586-023-06081-w","volume":"617","author":"R Naghavian","year":"2023","unstructured":"Naghavian, R. et al. Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma. Nature 617, 807\u2013817 (2023).","journal-title":"Nature"},{"key":"1755_CR19","doi-asserted-by":"publisher","unstructured":"Brandt, A., et al. UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: a randomized multicenter phase 2 trial. Medicine, 100647. https:\/\/doi.org\/10.1016\/j.medj.2025.100647 (2025).","DOI":"10.1016\/j.medj.2025.100647"},{"key":"1755_CR20","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.immuni.2020.06.024","volume":"53","author":"C Schultheiss","year":"2020","unstructured":"Schultheiss, C. et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity 53, 442\u2013455 e444 (2020).","journal-title":"Immunity"},{"key":"1755_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/hep.31473","volume":"73","author":"C Schultheiss","year":"2021","unstructured":"Schultheiss, C. et al. Next-generation immunosequencing reveals pathological T-cell architecture in autoimmune hepatitis. Hepatology 73, 1436\u20131448 (2021).","journal-title":"Hepatology"},{"key":"1755_CR22","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3389\/fimmu.2019.01897","volume":"10","author":"D Simnica","year":"2019","unstructured":"Simnica, D. et al. High-throughput immunogenetics reveals a lack of physiological T cell clusters in patients with autoimmune cytopenias. Front. Immunol. 10, 1897 (2019).","journal-title":"Front. Immunol."},{"key":"1755_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"1755_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.copbio.2020.07.010","volume":"65","author":"J Chiffelle","year":"2020","unstructured":"Chiffelle, J. et al. T-cell repertoire analysis and metrics of diversity and clonality. Curr. Opin. Biotechnol. 65, 284\u2013295 (2020).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1755_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nature22976","volume":"547","author":"J Glanville","year":"2017","unstructured":"Glanville, J. et al. Identifying specificity groups in the T cell receptor repertoire. Nature 547, 94\u201398 (2017).","journal-title":"Nature"},{"key":"1755_CR26","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41587-020-0505-4","volume":"38","author":"H Huang","year":"2020","unstructured":"Huang, H., Wang, C., Rubelt, F., Scriba, T. J. & Davis, M. M. Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening. Nat. Biotechnol. 38, 1194\u20131202 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1755_CR27","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/bioinformatics\/btz035","volume":"35","author":"Z Sethna","year":"2019","unstructured":"Sethna, Z., Elhanati, Y., Callan, C. G., Walczak, A. M. & Mora, T. OLGA: fast computation of generation probabilities of B- and T-cell receptor amino acid sequences and motifs. Bioinformatics 35, 2974\u20132981 (2019).","journal-title":"Bioinformatics"},{"key":"1755_CR28","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41592-022-01578-0","volume":"19","author":"M Goncharov","year":"2022","unstructured":"Goncharov, M. et al. VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2. Nat. Methods 19, 1017\u20131019 (2022).","journal-title":"Nat. Methods"},{"key":"1755_CR29","doi-asserted-by":"publisher","first-page":"W502","DOI":"10.1093\/nar\/gkz452","volume":"47","author":"SK Dhanda","year":"2019","unstructured":"Dhanda, S. K. et al. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res. 47, W502\u2013W506 (2019).","journal-title":"Nucleic Acids Res."},{"key":"1755_CR30","doi-asserted-by":"publisher","unstructured":"Zhou, W. et al. NeoTCR: an immunoinformatic database of experimentally-supported functional neoantigen-specific TCR sequences. Genomics Proteomics Bioinf. 23, https:\/\/doi.org\/10.1093\/gpbjnl\/qzae010 (2025).","DOI":"10.1093\/gpbjnl\/qzae010"},{"key":"1755_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01020-6","volume":"9","author":"L Paschold","year":"2025","unstructured":"Paschold, L. et al. Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer. NPJ Precis. Oncol. 9, 272 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1755_CR32","doi-asserted-by":"publisher","unstructured":"Bessell, C. A. et al. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight 5, https:\/\/doi.org\/10.1172\/jci.insight.135597 (2020).","DOI":"10.1172\/jci.insight.135597"},{"key":"1755_CR33","doi-asserted-by":"publisher","first-page":"S498","DOI":"10.1016\/j.annonc.2023.09.671","volume":"34","author":"E Baudin","year":"2023","unstructured":"Baudin, E. et al. 724O EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma\/paraganglioma (MPP): EOADR1-19\/SPENCER. Ann. Oncol. 34, S498\u2013S499 (2023).","journal-title":"Ann. Oncol."},{"key":"1755_CR34","doi-asserted-by":"publisher","first-page":"v67","DOI":"10.1093\/neuonc\/noad179.0265","volume":"25","author":"D Reardon","year":"2023","unstructured":"Reardon, D. et al. CTIM-25. EO2401 peptide immunotherapy + nivolumab +\/- bevacizumab in first recurrent glioblastoma: the phase 1\/2 EOGBM1-18\/ROSALIE study (NCT04116658). Neuro-Oncol. 25, v67\u2013v68 (2023).","journal-title":"Neuro-Oncol."},{"key":"1755_CR35","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2023.41.16_suppl.2020","volume":"41","author":"W Wick","year":"2023","unstructured":"Wick, W. et al. EO2401 (E) peptide immunotherapy + nivolumab (N) +\/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18\/ROSALIE. J. Clin. Oncol. 41, 2020\u20132020 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1755_CR36","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41591-020-01206-4","volume":"27","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","journal-title":"Nat. Med."},{"key":"1755_CR37","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/0008-5472.CAN-10-2693","volume":"71","author":"V Corbiere","year":"2011","unstructured":"Corbiere, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253\u20131262 (2011).","journal-title":"Cancer Res."},{"key":"1755_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin, A. J. et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature 647, 488\u2013497 (2025).","journal-title":"Nature"},{"key":"1755_CR39","doi-asserted-by":"publisher","unstructured":"Wang, X. S., and Fox, B. A. Bright side of the dark genome: antigens for next-gen cancer vaccines. J. Immunother. Cancer 14, https:\/\/doi.org\/10.1136\/jitc-2025-014075 (2026).","DOI":"10.1136\/jitc-2025-014075"},{"key":"1755_CR40","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ng.3822","volume":"49","author":"RO Emerson","year":"2017","unstructured":"Emerson, R. O. et al. Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire. Nat. Genet. 49, 659\u2013665 (2017).","journal-title":"Nat. Genet."},{"key":"1755_CR41","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00262-021-03047-7","volume":"71","author":"YHF Teng","year":"2022","unstructured":"Teng, Y. H. F. et al. Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. Cancer Immunol. Immunother. 71, 989\u2013998 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"1755_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"1755_CR43","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira, G. et al. Phenotype, specificity and avidity of antitumour CD8(+) T cells in melanoma. Nature 596, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"1755_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08534-1","volume":"10","author":"PC Rosato","year":"2019","unstructured":"Rosato, P. C. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat. Commun. 10, 567 (2019).","journal-title":"Nat. Commun."},{"key":"1755_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116738119","volume":"119","author":"N Cuburu","year":"2022","unstructured":"Cuburu, N. et al. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proc. Natl. Acad. Sci. USA. 119, e2116738119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"1755_CR46","doi-asserted-by":"publisher","unstructured":"Wu, K. et al. Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma. J. Immunother Cancer 11, https:\/\/doi.org\/10.1136\/jitc-2023-007528 (2023).","DOI":"10.1136\/jitc-2023-007528"},{"key":"1755_CR47","doi-asserted-by":"publisher","unstructured":"Landwehr, L. S. et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2019-000469 (2020).","DOI":"10.1136\/jitc-2019-000469"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01755-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:24:47Z","timestamp":1793276687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01755-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01755-8","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B. received institutional research grants from Merck, BMS, Hexal, Novartis, German Cancer Aid (Krebshilfe), German Research Foundation and the Federal Ministry of Education and Research as well as honoraria for lectures and advisory board meetings by Celgene, Janssen, Gilead, Merck, Roche, Amgen, Sanofi-Aventis and BMS. Enterome employed T.M., A.T., J.G.M. and L.C. at the time of this study. M.B. received funding from Enterome at the time of the study. All other authors declare that they have no potential conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"569"}}